Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain

Chi Kyung Kim, Xiu Li Yang, Young Ju Kim, In Young Choi, Han Gil Jeong, Hong Kyun Park, Dohoung Kim, Tae Jung Kim, Hyunduk Jang, Sang Bae Ko, Byung Woo Yoon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. In this context, we investigated the effects of long-term treatment with low-dose fimasartan on focal ischemia in rat brain. We induced focal ischemia in brain by transient intraluminal occlusion of middle cerebral artery (MCA) and administered low-dose (0.5 mg/kg) or regular doses (1 or 3 mg/kg) of fimasartan via intravenous routes. After the administration of low-dose (0.5 mg/kg) fimasartan, blood pressure did not decrease compared to the phosphate-buffered saline- (PBS-) control with MCA occlusion (MCAO) group. The infarct volume and ischemic cell death were reduced in the low-dose fimasartan-treated group (46 ± 41 mm3 for 0.5 mg/kg and 153 ± 47 mm3 for PBS-control with MCAO; P < 0.01) but not in the regular-dose groups. Low-dose fimasartan treatment improved functional recovery after ischemia and significantly decreased mortality. In our study, fimasartan reduced the degradation of IB and the formation of an inflammatory end-product, COX-2. As a result, the recruitment of inflammatory cells in the peri-infarct area decreased in fimasartan-treated group. We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation.

Original languageEnglish
Article number295925
JournalBioMed Research International
Volume2015
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Rats
Brain
Ischemia
Middle Cerebral Artery Infarction
Brain Ischemia
Phosphates
fimasartan
Angiotensin Receptor Antagonists
Blood pressure
Cell death
Atherosclerosis
Cell Death
Myocardial Infarction
Blood Pressure
Inflammation
Recovery
Degradation
Mortality

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Kim, C. K., Yang, X. L., Kim, Y. J., Choi, I. Y., Jeong, H. G., Park, H. K., ... Yoon, B. W. (2015). Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain. BioMed Research International, 2015, [295925]. https://doi.org/10.1155/2015/295925

Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain. / Kim, Chi Kyung; Yang, Xiu Li; Kim, Young Ju; Choi, In Young; Jeong, Han Gil; Park, Hong Kyun; Kim, Dohoung; Kim, Tae Jung; Jang, Hyunduk; Ko, Sang Bae; Yoon, Byung Woo.

In: BioMed Research International, Vol. 2015, 295925, 01.01.2015.

Research output: Contribution to journalArticle

Kim, CK, Yang, XL, Kim, YJ, Choi, IY, Jeong, HG, Park, HK, Kim, D, Kim, TJ, Jang, H, Ko, SB & Yoon, BW 2015, 'Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain', BioMed Research International, vol. 2015, 295925. https://doi.org/10.1155/2015/295925
Kim, Chi Kyung ; Yang, Xiu Li ; Kim, Young Ju ; Choi, In Young ; Jeong, Han Gil ; Park, Hong Kyun ; Kim, Dohoung ; Kim, Tae Jung ; Jang, Hyunduk ; Ko, Sang Bae ; Yoon, Byung Woo. / Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain. In: BioMed Research International. 2015 ; Vol. 2015.
@article{93ac57ec61494fc3917f6fec8e250578,
title = "Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain",
abstract = "Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. In this context, we investigated the effects of long-term treatment with low-dose fimasartan on focal ischemia in rat brain. We induced focal ischemia in brain by transient intraluminal occlusion of middle cerebral artery (MCA) and administered low-dose (0.5 mg/kg) or regular doses (1 or 3 mg/kg) of fimasartan via intravenous routes. After the administration of low-dose (0.5 mg/kg) fimasartan, blood pressure did not decrease compared to the phosphate-buffered saline- (PBS-) control with MCA occlusion (MCAO) group. The infarct volume and ischemic cell death were reduced in the low-dose fimasartan-treated group (46 ± 41 mm3 for 0.5 mg/kg and 153 ± 47 mm3 for PBS-control with MCAO; P < 0.01) but not in the regular-dose groups. Low-dose fimasartan treatment improved functional recovery after ischemia and significantly decreased mortality. In our study, fimasartan reduced the degradation of IB and the formation of an inflammatory end-product, COX-2. As a result, the recruitment of inflammatory cells in the peri-infarct area decreased in fimasartan-treated group. We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation.",
author = "Kim, {Chi Kyung} and Yang, {Xiu Li} and Kim, {Young Ju} and Choi, {In Young} and Jeong, {Han Gil} and Park, {Hong Kyun} and Dohoung Kim and Kim, {Tae Jung} and Hyunduk Jang and Ko, {Sang Bae} and Yoon, {Byung Woo}",
year = "2015",
month = "1",
day = "1",
doi = "10.1155/2015/295925",
language = "English",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain

AU - Kim, Chi Kyung

AU - Yang, Xiu Li

AU - Kim, Young Ju

AU - Choi, In Young

AU - Jeong, Han Gil

AU - Park, Hong Kyun

AU - Kim, Dohoung

AU - Kim, Tae Jung

AU - Jang, Hyunduk

AU - Ko, Sang Bae

AU - Yoon, Byung Woo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. In this context, we investigated the effects of long-term treatment with low-dose fimasartan on focal ischemia in rat brain. We induced focal ischemia in brain by transient intraluminal occlusion of middle cerebral artery (MCA) and administered low-dose (0.5 mg/kg) or regular doses (1 or 3 mg/kg) of fimasartan via intravenous routes. After the administration of low-dose (0.5 mg/kg) fimasartan, blood pressure did not decrease compared to the phosphate-buffered saline- (PBS-) control with MCA occlusion (MCAO) group. The infarct volume and ischemic cell death were reduced in the low-dose fimasartan-treated group (46 ± 41 mm3 for 0.5 mg/kg and 153 ± 47 mm3 for PBS-control with MCAO; P < 0.01) but not in the regular-dose groups. Low-dose fimasartan treatment improved functional recovery after ischemia and significantly decreased mortality. In our study, fimasartan reduced the degradation of IB and the formation of an inflammatory end-product, COX-2. As a result, the recruitment of inflammatory cells in the peri-infarct area decreased in fimasartan-treated group. We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation.

AB - Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. In this context, we investigated the effects of long-term treatment with low-dose fimasartan on focal ischemia in rat brain. We induced focal ischemia in brain by transient intraluminal occlusion of middle cerebral artery (MCA) and administered low-dose (0.5 mg/kg) or regular doses (1 or 3 mg/kg) of fimasartan via intravenous routes. After the administration of low-dose (0.5 mg/kg) fimasartan, blood pressure did not decrease compared to the phosphate-buffered saline- (PBS-) control with MCA occlusion (MCAO) group. The infarct volume and ischemic cell death were reduced in the low-dose fimasartan-treated group (46 ± 41 mm3 for 0.5 mg/kg and 153 ± 47 mm3 for PBS-control with MCAO; P < 0.01) but not in the regular-dose groups. Low-dose fimasartan treatment improved functional recovery after ischemia and significantly decreased mortality. In our study, fimasartan reduced the degradation of IB and the formation of an inflammatory end-product, COX-2. As a result, the recruitment of inflammatory cells in the peri-infarct area decreased in fimasartan-treated group. We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84942803517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942803517&partnerID=8YFLogxK

U2 - 10.1155/2015/295925

DO - 10.1155/2015/295925

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 295925

ER -